Evidence map›Paper›PMID 40003360›Full record

ReviewInternational journal of environmental research and public health2025

Psychedelics: Safety and Efficacy.

Norman Miller

Abstract readReview
In one paragraph

Review in International journal of environmental research and public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Norman MillerMedical College of Georgia, Augusta University, Augusta, GA 30912, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psychedelic research has experienced a renaissance in recent years, with many researchers exploring the possible therapeutic effects of these drugs. Medical institutions, universities, pharmaceutical companies, and governmental institutions alike have been showing an increase in support of this research, as shown through the recent establishment of various psychedelic research facilities across the United States. However, the safety and efficacy of psychedelic usage are not the focus of the existing research. Additionally, many of the studies on psychedelic use that have already been published lack the necessary scientific rigor required for studies of such medical importance. The current paper will discuss the issue of misleading information as well as poorly designed studies and what implications these have on the rescheduling of psychedelic drugs that are currently categorized as Schedule I. The current Schedule I status of psychedelics means that they are considered to have no legitimate medical value as well as a high potential for abuse. Furthermore, the current paper aims to discuss psychedelics while drawing awareness to the lack of the literature surrounding the safety and efficacy of psychedelics for medical use. This paper will also discuss the history of psychedelic use and abuse, the adverse effects of psychedelic use, and the role that personal and financial bias has within the psychedelic research field.

Indexed as

HallucinogensHumansHallucinogensaddictionefficacypsychedelicssafetytoxicity

Identifiers

PMID40003360
PMCPMC11855591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.